|
 Pharmacovigilance and Other Pharma Regulatory Developments 2010-2020What regulatory demands will pharma companies face from 2010 to 2020? Our new study will show you developments in pharma regulations - pre- and post-marketing - from 2010 onwards. How can regulatory developments help companies in the era of more-personalised medicine? You can have our report today, staying ahead. |
 Pharmaceutical Contract Manufacturing: Industry and Market Prospects 2010-2025How will the contract manufacturing sector adapt to the needs of pharma from 2010 onwards? Our new report will show you trends and prospects there. How will the sector and its customers face challenges and opportunities? We show commercial benefits for the pharma contract manufacturing sector and its customers, including revenue trends for 2010-2025. You can have that report today, staying ahead. |
 Biobanking for Medical R&D: Technology and Market 2010-2025Biobanking for Medical R&D: Technology and Market 2010-2025 reveals the opportunities and challenges the biobanking sector will face. These include consolidation and harmonisation of biobanking practices. Advances in genetic research, stem cell research and regenerative medicine increase the importance of biobanking, as well as its commercial potential. |
 Therapeutic Monoclonal Antibodies: World Market 2010-2025In 2009, the therapeutic monoclonal antibodies market generated total revenues of over $35bn worldwide. From 2010 onwards, this sector will benefit from new drugs and expanding indications for existing products, our latest study shows. New technologies will be an important driver of revenue growth. Intensive R&D activity is producing a strong R&D pipeline, filled with novel monoclonal antibodies, antibody fragments and antibody-drug conjugates. We expect significant opportunities for further commercial growth, as discussed in our latest report. |
 Prospects for Pharma Mergers, Acquisitions and Alliances 2010-2020Last year was important for pharmaceutical mergers and acquisitions, with total deal values in 2009 reaching almost $150bn. Driving this activity were three 'mega-mergers' at the heart of the industry, as Pfizer took over Wyeth, Roche bought the remaining shares in Genentech, and Merck & Co acquired Schering-Plough. Those historic deals signal the continued importance of mergers and acquisitions (M&A) as a strategy among pharma companies, with associated benefits and challenges. The importance of consolidation and alliances will increase from 2010 onwards, as companies adapt to changing conditions within the industry and market. |
 The Global OTC Pharmaceutical Market 2010-2025In 2009, the global over-the-counter (OTC) pharmaceutical market generated revenues of more than $60bn. Our analyses show that total OTC revenues will exceed $70bn by 2015. From 2010 onwards, Rx-to-OTC switching and the continuing importance of emerging healthcare markets will drive sales in this sector. Our forecasts reveal that the OTC pharma market will grow significantly from 2010 onwards. This report explains where future OTC switching and other developments will occur, providing you with the information that you need to understand the current OTC market and its future prospects. |
 Clinical Trials: World Market 2010-2025The market for clinical trial services has been expanding rapidly, with impressive revenue growth and expansion of the sector in recent years. Our new study shows how that sector will develop from 2010 onwards, with benefits to the pharma industry and clinical service providers. Clinical research organisations (CROs) are playing increasingly important roles in drug development worldwide, from conducting phase I trials to post-marketing studies. |
 Pharmaceutical Product Lifecycle Management 2010-2020The pharmaceutical industry currently faces marked challenges in its long-standing business model. Product lifecycle management (PLM) is being used to maximise the revenue-generating potential of pharmaceuticals, especially in their maturity, but also earlier on. In our new report - Pharmaceutical Product Lifecycle Management 2010-2020 - we examine the PLM strategies that pharmaceutical companies are using. Those measures range from reformulations, new combinations of drugs and expanded indication ranges, to the use of alliances, licensing, mergers and acquisitions. |
 Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025Our new report examines current and future prospects for the age-related macular degeneration (AMD) and diabetic retinopathy (DR) pharmaceutical markets. The global market for AMD and DR drugs exceeded $2.5bn in 2009, with growth from previous years. We predict that the overall market will expand from 2010 onwards. The rising prevalence of AMD and DR is due to aging populations worldwide and other changes. In particular, the world is facing a "diabetes epidemic", with soaring numbers of people with diabetes and related complications, including diabetic retinopathy. |
 Lyophilisation for Pharmaceuticals: Technology and Market 2010-2025Lyophilisation (also known as freeze drying or cryodesiccation) is an operation used for the preparation of stable pharmaceutical products. The market for lyophilisation has enjoyed strong growth in recent years, driven by new products and drug classes, especially in biotechnology. In recent years, the number of such products has been growing steadily. It is predicted that half of the injectable drugs approved in the next five years will require lyophilisation. In our new report, we predict that the global lyophilisation market will grow steadily in revenue and unit sales from 2010 to 2025. |
|